A typical retatrutide protocol runs 24 to 48 weeks, with some people continuing indefinitely
Combination therapies Besides the combination therapies described above, in patients with bridging fibrosis and cirrhosis, combining cilofexor (ACC inhibitor) and firsocostat (FXR agonist) for 48 weeks was well tolerated, showed beneficial effects on MASH disease parameters, and might improve fibrosis
Retatrutide takes these natural processes and intensifies them, resulting in profound appetite suppression, enhanced metabolic rate, and preferential fat oxidation
Side Effects and Considerations When Using GLP-1 for Weight Loss Using GLP-1 weight loss treatments can be transformative
Patients should not assume retatrutide is safer or better for them simply because it targets more receptors
The index single-nucleotide polymorphism (SNP) of the main association was rs10305420 ( P = 2.9 10 10 , reference allele C, effect allele T), which conferred an additional 0.641% BMI loss per T allele, approximately equivalent to an additional 0.76 kg weight loss per allele (95% CI, [1.27, 0.34] kg)
